These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 2202465)
21. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970 [TBL] [Abstract][Full Text] [Related]
22. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. Creutzig U; Zimmermann M; Lehrnbecher T; Graf N; Hermann J; Niemeyer CM; Reiter A; Ritter J; Dworzak M; Stary J; Reinhardt D J Clin Oncol; 2006 Sep; 24(27):4499-506. PubMed ID: 16983120 [TBL] [Abstract][Full Text] [Related]
23. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Graf M; Hecht K; Reif S; Pelka-Fleischer R; Pfister K; Schmetzer H Eur J Haematol; 2004 Feb; 72(2):89-106. PubMed ID: 14962246 [TBL] [Abstract][Full Text] [Related]
24. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients. Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163 [TBL] [Abstract][Full Text] [Related]
25. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial. Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281 [TBL] [Abstract][Full Text] [Related]
26. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma. Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918 [TBL] [Abstract][Full Text] [Related]
28. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254 [TBL] [Abstract][Full Text] [Related]
29. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). Witz F; Sadoun A; Perrin MC; Berthou C; Brière J; Cahn JY; Lioure B; Witz B; François S; Desablens B; Pignon B; Le Prisé PY; Audhuy B; Caillot D; Casassus P; Delain M; Christian B; Tellier Z; Polin V; Hurteloup P; Harousseau JL Blood; 1998 Apr; 91(8):2722-30. PubMed ID: 9531581 [TBL] [Abstract][Full Text] [Related]
30. GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Heil G; Chadid L; Hoelzer D; Seipelt G; Mitrou P; Huber C; Kolbe K; Mertelsmann R; Lindemann A; Frisch J Leukemia; 1995 Jan; 9(1):3-9. PubMed ID: 7845026 [TBL] [Abstract][Full Text] [Related]
31. GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS. Winer ES; Miller KB; Chan GW Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):11-4. PubMed ID: 15934494 [TBL] [Abstract][Full Text] [Related]
32. Changing response of clonogenic myeloid leukemia blasts to granulocyte-macrophage colony-stimulating factor (GM-CSF) during anti-leukemic therapy--a case report on the basis of a clinical phase II trial. Hiddemann W; Zühlsdorf M; Wörmann B; Koenigsmann M; Büchner T Leuk Res; 1990; 14(4):347-52. PubMed ID: 2185381 [TBL] [Abstract][Full Text] [Related]
33. GM-CSF treatment in aplasia after cytotoxic therapy. Gattringer C; Thaler J; Drach J; Micksche M; Huber H Onkologie; 1989 Feb; 12(1):16-8. PubMed ID: 2654787 [TBL] [Abstract][Full Text] [Related]
34. Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Estey EH; Dixon D; Kantarjian HM; Keating MJ; McCredie K; Bodey GP; Kurzrock R; Talpaz M; Freireich EJ; Deisseroth AB Blood; 1990 May; 75(9):1766-9. PubMed ID: 2184901 [TBL] [Abstract][Full Text] [Related]
35. Treatment of de novo acute myelogenous leukemia with recombinant granulocyte macrophage-colony-stimulating factor in combination with standard induction chemotherapy: effect of granulocyte macrophage-colony-stimulating factor on white blood cell counts. Valent P; Sillaber C; Geissler K; Andreeff M; Tafuri A; Vieder L; Schulz G; Lechner K; Bettelheim P Med Pediatr Oncol Suppl; 1992; 2():18-22. PubMed ID: 1306881 [TBL] [Abstract][Full Text] [Related]
36. Reversible leukaemic regrowth under GM-CSF treatment after chemotherapy for AML. Koenigsmann M; Hiddemann W; Büchner T Leuk Res; 1991; 15(1):37-41. PubMed ID: 1997744 [TBL] [Abstract][Full Text] [Related]
37. Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia : can they improve clinical decision making? Bennett CL; Schumock GT Drugs Aging; 2003; 20(7):479-83. PubMed ID: 12749746 [TBL] [Abstract][Full Text] [Related]
38. Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. Heuser M; Zapf A; Morgan M; Krauter J; Ganser A Ann Hematol; 2011 Mar; 90(3):273-81. PubMed ID: 20838825 [TBL] [Abstract][Full Text] [Related]
39. The role of GM-CSF in the treatment of acute myeloid leukemia. Büchner T; Hiddemann W; Wörmann B; Rottmann R; Maschmeyer G; Ludwig WD; Zühlsdorf M; Buntkirchen K; Sander A; Aswald J Leuk Lymphoma; 1993; 11 Suppl 2():21-4. PubMed ID: 8124228 [TBL] [Abstract][Full Text] [Related]
40. Decrease in arterial oxygen partial pressure within the first 24 h of rhGM-CSF administration in AML patients. Zühlsdorf M; von Eiff M; Thomas M; Büchner T Eur J Haematol; 1997 Nov; 59(5):293-8. PubMed ID: 9414640 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]